336 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22819 | Available tumor tissue | Martine Piccart | Multiple | Institut Jules Bordet | PRECISION | Trial closed | The Jules Bordet Institute Program for Molecular Profiling of Metastatic Lesions : Feasibility | martine.piccart@hubruxelles.be | |||
| 22701 | ECOG 0, 1 or 2 | Philippe Aftimos | Multiple | BSMO | PRECISION 1 | Trial open for recruitment | PRECISION 1 BSMO 2014-2 The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment | philippe.aftimos@hubruxelles.be | |||
| 22721 | Homologous recombination deficiency | Daphné t'Kint de Roodenbeke | Multiple | BSMO | PRECISION 2 | Trial closed for recruitment | Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes (PRECISION 2) | daphne.tkint@hubruxelles.be | 2 | 2 | |
| 22648 | Activating EGFR mutation or HER2 mutation or HER3 mutation | Philippe Aftimos | Breast | UZ-Brussel | Precision 2 | Trial closed for recruitment | An open explorative phase II, open-label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22647 | after one line | Alex De Caluwé | Multiple | UZ-Gent | PRIMMO trial - Pembrolizumab-Radiotherapy-Immunomodulator trial | Trial closed | A phase II Investigation of Pembrolizumab (Keytruda) in combination with radiation and an immune modulatory cocktail in patients with cervical and uterine cancer | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22624 | ER+/HER2-. Metastatic. Endocrine resistant. Palbociclib | Michail Ignatiadis | Breast | IBCSG | PYTHIA IBCSG 53-14 / BIG 14-04 | Trial closed | PYTHIA IBCSG 53-14 A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 29680 | Nuria Kotecki | Multiple | Pyxis Oncology | PYX-201-101 | Trial open for recruitment | Phase 1, First-in-Human, Open-label, Multicenter Study Evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PYX-201 in subjects with advanced solid tumors (PYX-201-101) | Nuria.Kotecki@hubruxelles.be | 1 | 1 | ||
| 22726 | Rectal adenocarcinoma requiring preoperative radiotherapy | Alain Hendlisz | Rectum | GHdC | R-IMMUNE | Trial closed for recruitment | A Phase IB/II study to evaluate safety and efficacy of Atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with localized rectal cancer (R-IMMUNE). | alain.hendlisz@hubruxelles.be | 1b | 1 | |
| 22722 | Recurrent, persistent, and/or metastatic | Laura Polastro | Uterus | Regeneron Pharmaceuticals, Inc. | R2810-ONC-1676 | Trial closed | An open-label, randomized, phase 3 clinical trial of REGN2810 versus investigator's choice of chemotherapy in recurrent or metastatic cervical carcinoma | laura.polastro@hubruxelles.be | 3 | 3 | |
| 22934 | - The treatment decision to Radium-223 needs to be made independent from and before patient enrollment in the study - Patients with histologically or cytologically confirmed castration resistant adenocarcinoma of the prostate with bone metastases |
Carlos Artigas Guix | prostate | Bayer | REASSURE | Trial closed for recruitment | REASSURE, Radium-223 alpha Emitter Agent in Safety Study in mCRPC popUlation for long-teRm Evaluation (Bayer 16913) | carlos.artigas@hubruxelles.be | 4 | 4 | |
| 28772 | Alain Hendlisz | Multiple | Institut Jules Bordet | REGINA | Trial open for recruitment | A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III rectAl cancer | alain.hendlisz@hubruxelles.be | 2 | 2 | ||
| 22822 | EGFR+ | Yassine Lalami | Multiple | Glycotope | RESGEX | Trial closed | Randomized, controlled, open-label, multicenter, phase II study to evaluate the efficacy and safety of CetuGEXTM plus chemotherapy in comparison to cetuximab plus chemotherapy for the treatment of patients with stage III/IV recurrent and/or metastatic squamous cell carcinoma of the head and neck | yassine.lalami@hubruxelles.be | 2 | 2 | |
| 29780 | Francesco Sclafani | Multiple | Inspirna | RGX-202-002 | Trial open for recruitment | A randomized Phase 2 Study of ompenaclid versus placebo in combination with FOLFIRI plus bevacizumab in patients with previously treated RAS mutant advanced or metastatic colorectal cancer | francesco.sclafani@hubruxelles.be | 2 | 2 | ||
| 28735 | Evandro De Azambuja | Breast | UZ-K.U.Leuven | RIBOB | Trial closed for recruitment | A phase IV Study to collect data on the efficacy and safety of RIBociclib in combination with letrozole in Older women (?70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease | 4 | 4 |